Home > Formulary : Adult > Chapters > 5. Infections >
BNSSG Adult Joint Formulary
5.7 Treatment of COVID-19
Last edited: 25-06-2024
5.7.1 COVID-19
Neutralising monoclonal antibodies (nMABs) in the treatment of COVID-19
Sotrovimab (Xevudy®) (TLS Red)
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here
Casirivimab and Imdevimab (TLS Red)
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Tocilizumab (TLS Red)
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Antivirals in the treatment of COVID-19
Molnupiravir (Lagevrio®) (TLS Red)
- For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here
Nirmatrelvir and Ritonavir (Paxlovid®) (TLS Red)
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here
- SPS guidance on medicines interactions with nirmatrelvir and ritonavir (Paxlovid®) to be used alongside the NHSE/I commissioning policy here
Remdesivir (TLS Red)
- NICE TA971 Remdesivir for treating COVID-19
- For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here
Janus-associated tyrosine kinase (JAK) inhibitors in the treatment of COVID-19
Baricitinib (TLS Red)
- For use as per NHS Clinical Commissioning Policy. See CAS Alert documents here
Contact us
Got a question or comment about the Joint Formulary?
Please use the email address below to contact us and we will endeavour to respond within 2 working days.